4/15/2014 9:34:11 AM
SILVER SPRING, Md., April 15, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United Kingdom, to handle every aspect of Nuvilex's late-phase clinical trials in pancreatic cancer as Nuvilex's Contract Research Organization (CRO). The trials, which will focus on treatment for advanced stage pancreatic cancer, will involve Nuvilex's pancreatic cancer treatment (a combination of the proprietary "Cell in-a-Box®" live-cell encapsulation technology and the cancer drug ifosfamide) which has already proved effective in early stage trials.
Help employers find you! Check out all the jobs and post your resume.
comments powered by